Per the notice below, the Centers for Medicare and Medicaid Services (CMS) is seeking public comments on its proposed Medicare Part D $2 Drug List Model.

CMS Seeks Feedback on Medicare $2 Drug List Model, Sample $2 Drug List, and Outreach

Today, the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), released a Request for Information (RFI) and a sample list of prescription drugs that the agency preliminarily intends to include under the proposed Medicare $2 Drug List Model, which was developed in accordance with President Biden’s Executive Order 14087, “Lowering Prescription Drug Costs for Americans."  Under the model, people enrolled in a participating Medicare prescription drug coverage (Part D) plan would have access to these drugs for a low, fixed copayment of no more than $2 for a month’s supply per drug.  The model would provide individuals more certainty about the out-of-pocket costs for these generic covered Part D drugs that treat common medical conditions.  CMS issued this RFI to support continued development of the model.  The Center for Medicare and Medicaid Innovation’s (Innovation Center's) Medicare $2 Drug List Model aims to test whether a simplified approach to offering low-cost, clinically important generic drugs can:

• Improve medication adherence,
• Lead to better health outcomes, and
• Improve satisfaction with the Part D prescription drug benefit among people with Medicare and prescribers.

Participation in the model would be voluntary for Part D sponsors and, pending further development, could start as early as January 2027.  Details on the Medicare $2 Drug List Request for Information can be found at Medicare $2 Drug List webpage.  Additional details on the Medicare $2 Drug List Model were also released in October 2023 in the “CMS Innovation Center’s One-Year Update on the Executive Order to Lower Prescription Drug Costs for Americans” blog post.  Information on how to submit comments can be found on: https://surveys.cms.gov/jfe/form/SV_40iDHQWMNuVfyGq.  Comments must be submitted by December 9, 2024, and will only be accepted through the link above.